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A 43-year-old Filipino woman, never-smoker, was diag-nosed with stage IV adenocarcinoma of the lung in
February 2009, with metastatic disease to the liver and brain.
The biopsies of the lung mass and liver confirmed poorly
differentiated, TTF-1-positive, EGFR-mutated (exon 19) ad-
enocarcinoma of the lung. The patient underwent a craniot-
omy followed by brachytherapy for the isolated brain metas-
tases. Subsequently, she initiated erlotinib plus celecoxib
versus placebo on a clinical trial in April 2009, to which she
responded for 12 months. In February 2010, she initiated
second-line carboplatin/pemetrexed/bevacizumab for six cy-
cles with complete resolution of the positron emission tomog-
raphy uptake to the lung primary and liver metastases. The
patient started maintenance bevacizumab in June 2010. In
February 2011, she presented with left shoulder pain with
absence of trauma or bone metastases. Magnetic resonance
imaging of the shoulder revealed avascular necrosis of the left
humeral head (Figure 1). The positron emission tomography/
computed tomography scan showed mild fluorodeoxyglucose
uptake to the left shoulder and a stable, fluorodeoxyglucose-
negative, left upper lobe mass (Figure 2). After the diagnosis
of avascular necrosis was made, bevacizumab was discontin-
ued and the patient initiated maintenance pemetrexed. Her
pain responded to anti-inflammatory medications.
Avascular necrosis of the femoral head has been re-
ported in two patients with colorectal cancer receiving bev-
acizumab and one patient receiving sunitinib.1 Prolonged
antiangiogenic therapy may impair the bone metabolism
leading to osteonecrosis.2 To our knowledge, this is a first
report of osteonecrosis of the humeral head in a patient
treated with bevacizumab alone without bisphosphonates or
other agents with increased risk of bone necrosis.
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FIGURE 1. Magnetic resonance imaging of the left shoul-
der showing abnormal bone marrow signal in the left hu-
meral head consistent with avascular necrosis.
FIGURE 2. Positron emission tomography image showing
mild fluorodeoxyglucose uptake to the left humeral head.
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